Sphingosine kinase inhibitors and cancer: seeking the golden sword of Hercules

Susan Pyne, Robert Bittman, Nigel Pyne

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

There is considerable evidence that sphingosine kinases play a key role in cancer progression, which might involve positive selection of cancer cells that have been provided with a survival and growth advantage as a consequence of overexpression of the enzyme. Therefore, inhibitors of sphingosine kinase represent a novel class of compounds that have potential as anticancer agents. Poor inhibitor potency is a major issue that has precluded successful translation of these compounds into the clinic. However, recent discoveries have shown that sphingosine kinase 1 is an allosteric enzyme and that some inhibitors offer improved effectiveness by inducing proteasomal degradation of the enzyme or having nanomolar potency. Herein, we provide a perspective about these recent developments and highlight the importance of translating basic pharmacologic and biochemical findings on sphingosine kinase into new drug discovery programs for treatment of cancer.
Original languageEnglish
Pages (from-to)6576-6582
Number of pages7
JournalCancer Research
Volume71
Issue number21
Early online date22 Sep 2011
DOIs
Publication statusPublished - 2011

Fingerprint

Neoplasms
Enzyme Inhibitors
Enzymes
Drug Discovery
Antineoplastic Agents
sphingosine kinase
Growth

Keywords

  • sphingosine kinase inhibitors
  • cancer
  • hercules
  • golden sword

Cite this

@article{01454a4afef14ceda341633887e56eb3,
title = "Sphingosine kinase inhibitors and cancer: seeking the golden sword of Hercules",
abstract = "There is considerable evidence that sphingosine kinases play a key role in cancer progression, which might involve positive selection of cancer cells that have been provided with a survival and growth advantage as a consequence of overexpression of the enzyme. Therefore, inhibitors of sphingosine kinase represent a novel class of compounds that have potential as anticancer agents. Poor inhibitor potency is a major issue that has precluded successful translation of these compounds into the clinic. However, recent discoveries have shown that sphingosine kinase 1 is an allosteric enzyme and that some inhibitors offer improved effectiveness by inducing proteasomal degradation of the enzyme or having nanomolar potency. Herein, we provide a perspective about these recent developments and highlight the importance of translating basic pharmacologic and biochemical findings on sphingosine kinase into new drug discovery programs for treatment of cancer.",
keywords = "sphingosine kinase inhibitors, cancer, hercules, golden sword",
author = "Susan Pyne and Robert Bittman and Nigel Pyne",
year = "2011",
doi = "10.1158/0008-5472.CAN-11-2364",
language = "English",
volume = "71",
pages = "6576--6582",
journal = "Cancer Research",
issn = "0008-5472",
number = "21",

}

Sphingosine kinase inhibitors and cancer : seeking the golden sword of Hercules. / Pyne, Susan; Bittman, Robert; Pyne, Nigel.

In: Cancer Research, Vol. 71, No. 21, 2011, p. 6576-6582.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sphingosine kinase inhibitors and cancer

T2 - seeking the golden sword of Hercules

AU - Pyne, Susan

AU - Bittman, Robert

AU - Pyne, Nigel

PY - 2011

Y1 - 2011

N2 - There is considerable evidence that sphingosine kinases play a key role in cancer progression, which might involve positive selection of cancer cells that have been provided with a survival and growth advantage as a consequence of overexpression of the enzyme. Therefore, inhibitors of sphingosine kinase represent a novel class of compounds that have potential as anticancer agents. Poor inhibitor potency is a major issue that has precluded successful translation of these compounds into the clinic. However, recent discoveries have shown that sphingosine kinase 1 is an allosteric enzyme and that some inhibitors offer improved effectiveness by inducing proteasomal degradation of the enzyme or having nanomolar potency. Herein, we provide a perspective about these recent developments and highlight the importance of translating basic pharmacologic and biochemical findings on sphingosine kinase into new drug discovery programs for treatment of cancer.

AB - There is considerable evidence that sphingosine kinases play a key role in cancer progression, which might involve positive selection of cancer cells that have been provided with a survival and growth advantage as a consequence of overexpression of the enzyme. Therefore, inhibitors of sphingosine kinase represent a novel class of compounds that have potential as anticancer agents. Poor inhibitor potency is a major issue that has precluded successful translation of these compounds into the clinic. However, recent discoveries have shown that sphingosine kinase 1 is an allosteric enzyme and that some inhibitors offer improved effectiveness by inducing proteasomal degradation of the enzyme or having nanomolar potency. Herein, we provide a perspective about these recent developments and highlight the importance of translating basic pharmacologic and biochemical findings on sphingosine kinase into new drug discovery programs for treatment of cancer.

KW - sphingosine kinase inhibitors

KW - cancer

KW - hercules

KW - golden sword

UR - http://www.scopus.com/inward/record.url?scp=80155127315&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-2364

DO - 10.1158/0008-5472.CAN-11-2364

M3 - Article

VL - 71

SP - 6576

EP - 6582

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 21

ER -